Using rafts to enhance bioavailability of ibandronate
Researchers have developed a novel tablet formulation of ibandronate which increases the oral bioavailability of the drug by releasing it from a hydrogel raft formed in the stomach.
List view / Grid view
Researchers have developed a novel tablet formulation of ibandronate which increases the oral bioavailability of the drug by releasing it from a hydrogel raft formed in the stomach.
Researchers have developed Metabolite Translator, a system that can predict what the in vivo metabolites of a drug could be in order to identify its potential toxicity.
A clinical trial in the UK has shown that lopinavir-ritonavir is not an effective treatment for patients admitted to hospital with COVID-19.
Novel programmed cell death protein 1 immunotherapies for cervical cancer have demonstrated success in two Phase II clinical trials in the US.
A new report has found that three quarters of dose manufacturing facilities acquired by dedicated CMOs in 2019 were in Europe.
Five labs have been selected by the Coalition for Epidemic Preparedness Innovations (CEPI) to act as a global network for the assessment of COVID-19 vaccine immunogenicity.
Italy and India were found to be the only countries to have improved their pharma economy score in 2020, according to the CPhI Pharma Index.
Treatment with Zolgensma® (onasemnogene abeparvovec) resulted in rapid and sustained improvement in motor function in spinal muscular atrophy (SMA) patients.
A new opinion piece from Watson-Marlow Fluid Technology Group has been launched.
The EMA's human medicines committee has initiated a rolling review of AstraZeneca's COVID-19 vaccine candidate to test its efficacy.
Warnings about addiction will be added to the patient information leaflets of opioids, the MHRA has announced.
Jasper Bovenberg and colleagues argue that the General Data Protection Regulation (GDPR) and associated guidelines has frustrated COVID-19 research, potentially harming global pandemic response efforts.
New research suggests male predominance in COVID-19 expert groups and task forces is undermining the pandemic response.
A Phase I clinical trial to test an intranasal COVID-19 vaccine spray has been given regulatory approval in China and is expected to begin in November.
The experimental COVID-19 vaccine, mRNA-1273, was well-tolerated and elicited a strong immune response in older adults during a Phase I trial.